Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Inclusion Criteria:

* Patients must be platinum resistant
* No prior anthracycline use
* PS ≤ 2
* Lab values within certain limits (ANC \> 1000, platelets \> 100,000; ALT, AST 2x ULN, creatinine \< 2.0);
* No more than 3 prior chemotherapy regimens, only 2 of which can have included platinum-containing regimens.
* Use of effective means of contraception in subjects of child-bearing potential

Exclusion Criteria:

* Disease-Specific Exclusions:

  * Evidence of complete or partial bowel obstruction
  * Need for IV hydration or TPN
  * \> 2 prior abdominal surgeries
  * History of gastrointestinal perforation
  * Gastrointestinal perforation due to any other cause within the last 6 months
* General Medical Exclusions:

  * Inability to comply with study and/or follow-up procedures
  * Life expectancy of less than 12 weeks
  * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study
* Avastin-Specific Exclusions:

  * Inadequately controlled hypertension (defined as systolic blood pressure greater than 150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications)
  * Any prior history of hypertensive crisis or hypertensive encephalopathy
  * New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E of the protocol)
  * History of myocardial infarction or unstable angina within 6 months prior to study enrollment
  * History of stroke or transient ischemic attack within 6 months prior to study enrollment
  * Known CNS disease
  * Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
  * Symptomatic peripheral vascular disease
  * Evidence of bleeding diathesis or coagulopathy
  * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
  * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
  * History of abdominal fistula, or intra-abdominal abscess within 6 months prior to study enrollment
  * Serious, non-healing wound, ulcer, or bone fracture
  * Proteinuria at screening as demonstrated by either

    * Urine protein:creatinine (UPC) ratio no less than 1.0 at screening OR
    * Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).
  * Known hypersensitivity to any component of Avastin
  * Pregnant (positive pregnancy test) or lactating. No effective means of contraception (men and women) in subjects of child-bearing potential